A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds Ozempic, Wegovy, Mounjaro or Zepbound, may help users overcome alcoholism and opioid addiction.

In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and suicide attempts compared to adolescents who didn't.

Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and alcohol intoxication, a large real-world study suggested.

The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down substance use cravings too.

New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people with substance use disorders. These medications, often prescribed for diabetes and weight issues,

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.